Viatris: 2021 Is Trough Year For Earnings But Revenues A Trickier Prospect

Company ‘Very, Very Pleased’ With Q1 Financials

Committed to greater transparency following its formation in November, Viatris published first-quarter financial results that met top- and bottom-line expectations. However, the US-based company promised to update the market for meeting revenue projections in 2021.

Businessman draws a statistical trend line
Viatris has “at this point” reaffirmed full-year 2021 guidance • Source: Shutterstock

Viatris “continues to feel strongly that 2021 is our trough year” in terms of profitability but concedes that group revenue is a harder metric to pin down given several uncertainties and challenges, as the combination of Mylan and Pfizer’s Upjohn published its first full quarter of financial results and tentatively reaffirmed full-year 2021 financial guidance.

Adjusted earnings before interest, tax, depreciation and amortization of $1.64bn for the first quarter of the year aligned with “the...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business